J&J woos Mer­ck­'s Math­ai Mam­men to helm of phar­ma R&D, Hait takes over on ex­ter­nal in­no­va­tion

J&J is ex­e­cut­ing a change­up in the lead­er­ship of its multi­bil­lion-dol­lar R&D group.

The phar­ma gi­ant, which re­cent­ly sig­naled plans to ex­pand its drug pipeline — which costs about $7 bil­lion a year to op­er­ate (the to­tal R&D bud­get was $9.1 bil­lion last year)— re­cruit­ed Mer­ck SVP Math­ai Mam­men to take Bill Hait’s role as phar­ma R&D chief, ac­cord­ing to a state­ment out Wednes­day night.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER